Advertisement

Topics

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

2016-12-01 16:08:22 | BioPortfolio

Summary

The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.

Description

IDH305 is an orally available, brain-penetrant, mutant-selective allosteric IDH1 inhibitor that blocks mutant IDH1-dependent production of 2-HG.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Glioma

Intervention

IDH305

Location

Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center
New York
New York
United States
10016

Status

Not yet recruiting

Source

New York University School of Medicine

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-12-01T16:08:22-0500

Clinical Trials [254 Associated Clinical Trials listed on BioPortfolio]

Phase 2 Study of IDH305 in Low Grade Gliomas

Cohort A - neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, ra...

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.

Seizure Treatment in Glioma

Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studiessupporting the use of one specific anticonvulsant in glioma pa...

Phase IIa Safety and Light Dose-Escalation Study in Patients With Primary or Recurrent/High-Grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of prim...

ANG1005 in Patients With Recurrent High-Grade Glioma

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safe...

PubMed Articles [439 Associated PubMed Articles listed on BioPortfolio]

Induction of specific T helper-9 cells to inhibit glioma cell growth.

The effects of Staphylococcal enterotoxin B (SEB) on regulation of immune response have been recognized; whether SEB can enhance the effects of immunotherapy on glioma remains to be investigated. This...

Dysregulation of microRNA-128 expression in WHO grades 2 glioma is associated with glioma-associated epilepsy: Down-regulation of miR-128 induces glioma-associated seizure.

Approximately 80% of glioma patients will experience at least one seizure activity during the course of the disease, and because the etiology of glioma-related seizure is most likely multifactorial an...

MiR-29b inhibits the growth of glioma via MYCN dependent way.

MiR-29b is widely involved in diverse cancers. We plan to study its role in glioma. The expression of miR-29b was detected by real-time polymerase chain reaction (PCR) and we found the expression of m...

Forkhead Box A2 (FOXA2) inhibits the invasion and tumorigenesis in glioma cells.

The forkhead Box A2 (FOXA2) is the key transcriptional factor that plays an important role in tumorigenesis. However, until now, the expression pattern and role of FOXA2 in glioma have yet to be eluci...

MicroRNA-105 targets SOX9 and inhibits human glioma cell progression.

Growing evidence indicates that microRNAs (miRNAs) play vital roles in glioma progression by directly regulating multiple targets. Here, we found that miR-105 expression was significantly decreased an...

Medical and Biotech [MESH] Definitions

A malignant BRAINSTEM neoplasm of the PONS. They are more commonly found in children than adults.

A BRAIN-specific hyalectin that may play a role in terminally differentiating NEURONS. It is found highly overexpressed in primary BRAIN TUMORS and in experimental models of GLIOMA.

Rare, slow-growing, benign intraventricular tumors, often asymptomatic and discovered incidentally. The tumors are classified histologically as ependymomas and demonstrate a proliferation of subependymal fibrillary astrocytes among the ependymal tumor cells. (From Clin Neurol Neurosurg 1997 Feb;99(1):17-22)

Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.

Benign and malignant neoplasms that arise from the optic nerve or its sheath. OPTIC NERVE GLIOMA is the most common histologic type. Optic nerve neoplasms tend to cause unilateral visual loss and an afferent pupillary defect and may spread via neural pathways to the brain.

More From BioPortfolio on "Trial of IDH305 in IDH1 Mutant Grade II or III Glioma"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial